--- title: "SAB Biotherapeutics (SABS) news: offering and convertible notes" url: "https://aibio.space/companies/sab-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SABS offering and convertible notes news: SAB Biotherapeutics agrees to $175 million private placement of Series B preferred stock. SAB Biotherapeutics, Inc." --- SABS SAB Biotherapeutics, Inc. NASDAQ · United States # SAB Biotherapeutics (SABS) news SABS offering and convertible notes news Financings · 2025-07-21 ## [SAB Biotherapeutics agrees to $175 million private placement of Series B preferred stock](https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/) SAB Biotherapeutics expects about $175 million in gross proceeds from Series B preferred stock, convertible into 100,000,000 common shares at $1.75. Warrants could bring in up to $284 million more, and the conversion rights wait on a stockholder vote. ## Latest SAB Biotherapeutics news 1. 2025-07-21 Financings [SAB Biotherapeutics agrees to $175 million private placement with Sanofi](https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/) SAB will issue convertible preferred stock convertible at $1.75 per share, plus warrants that could bring up to $284 million more if exercised in full. It expects cash to last into the middle of 2028. ## SAB Biotherapeutics at a glance - **Ticker**: SABS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $102.6 million ### Related companies - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) NASDAQ: STOK - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) NASDAQ: CABA - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [Cell Source](https://aibio.space/companies/cell-source/) OTC: CLCS - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) NASDAQ: BSEM - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) NASDAQ: COGT - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) NASDAQ: IPSC ### Also on NASDAQ - [Outset Medical](https://aibio.space/companies/outset-medical/) OM - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) AVLN - [Evolus](https://aibio.space/companies/evolus/) EOLS - [PepGen](https://aibio.space/companies/pepgen/) PEPG - [AtriCure](https://aibio.space/companies/atricure/) ATRC - [QuidelOrtho](https://aibio.space/companies/quidelortho/) QDEL ## What SAB Biotherapeutics does SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Its platform uses transchromosomic cattle, called Tc-Bovine, to produce hIgG without human plasma donors. The company focuses on type 1 diabetes (T1D) and other autoimmune disorders. Its wholly owned lead candidate, SAB-142, is a multi-specific, fully human anti-thymocyte globulin designed to delay onset and potentially prevent progression in Stage 3 T1D patients. The company says the mechanism of action has been clinically validated with rabbit anti-thymocyte globulin, and that data from approximately 800 human subjects have been treated with antibodies produced by its platform. The company started a registrational Phase 2b study called SAFEGUARD in the third quarter of 2025 and dosed its first patient in December 2025. In May 2025 it confirmed with the FDA its intent to use SAFEGUARD data as supportive evidence for future approval. The company also states that its regulatory pathway has been established with the FDA, the MHRA and the TGA in Australia. | Product or program | What it is | Stage | |---|---|---| | SAB-142 | Multi-specific, fully human anti-thymocyte globulin for Stage 3 T1D | Phase 2b registrational (SAFEGUARD); first patient dosed December 2025 | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/sabs-20251231.htm). ## SAB Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | | Research and development | [$34.4 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | | Net income (loss) | [$13.3 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | [-$34.1 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | | Cash from operations | [-$44.8 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | [-$34.3 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | | Cash and equivalents | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1833214/000119312526336783/) | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | | Short-term investments | [$86.1 million](https://www.sec.gov/Archives/edgar/data/1833214/000119312526336783/) | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.3 million, plus short-term investments of $94.4 million, $102.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about SAB Biotherapeutics Has SAB Biotherapeutics raised money recently? Our latest story on this, dated Jul 21, 2025: "SAB Biotherapeutics agrees to $175 million private placement of Series B preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/). Has SAB Biotherapeutics sold convertible notes? Our latest story on this, dated Jul 21, 2025: "SAB Biotherapeutics agrees to $175 million private placement of Series B preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/). What is the ticker symbol of SAB Biotherapeutics? SAB Biotherapeutics, Inc. trades under the ticker SABS on NASDAQ. Where is SAB Biotherapeutics listed? SAB Biotherapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of SAB Biotherapeutics? The SEC Central Index Key (CIK) for SAB Biotherapeutics, Inc. is 1833214. Its filings are on SEC EDGAR. How many shares does SAB Biotherapeutics have outstanding? 90,986,368 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is SAB Biotherapeutics listed under? Our directory records SAB Biotherapeutics, Inc. under United States. What does SAB Biotherapeutics do? Our directory classifies SAB Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of SAB Biotherapeutics? The ISIN recorded for SAB Biotherapeutics, Inc. is US78397T2024. Does aibio.space cover SAB Biotherapeutics? aibio.space lists SAB Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is SAB Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. What does SAB Biotherapeutics develop? SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Its platform uses transchromosomic cattle, called Tc-Bovine, to produce hIgG without human plasma donors. What is SAB-142 from SAB Biotherapeutics? SAB-142: Multi-specific, fully human anti-thymocyte globulin for Stage 3 T1D Stage: Phase 2b registrational (SAFEGUARD); first patient dosed December 2025. What was SAB Biotherapeutics's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is SAB Biotherapeutics profitable? SAB Biotherapeutics, Inc. reported net income of $13.3 million for the fiscal year ended Dec 31, 2025, and used $44.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: SAB Biotherapeutics Members talk about SAB Biotherapeutics (SABS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at SAB Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1833214/000119312526110666/424b5_sabs_fy26_prosupp.htm) 2. 2025-12-29 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/sabs-20251229.htm) 3. 2025-07-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1833214/000095017025097078/sabs-ex99_1.htm) 4. 2025-02-05 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1833214/000095017025014627/sabs-20250130.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SABS on TradingView](https://www.tradingview.com/symbols/NASDAQ-SABS/). ## SEC filings and registration - **SEC name**: SAB Biotherapeutics, Inc. - **CIK**: 1833214 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SABS (Nasdaq), SABSW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 777 W 41ST ST, MIAMI BEACH, FL, 33140 - **Phone**: 305-845-2813 - **Shares outstanding**: 90,986,368 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Big Cypress Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1833214/000119312526419769/sabs-20261013.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1833214/000119312526336783/sabs-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/sabs-20260707.htm) filed 2026-07-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/sabs-20260618.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1833214/000119312526218195/sabs-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/sabs-20260428.htm) filed 2026-05-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1833214/000119312526197607/sabs_def14a_fy26agm.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1833214/000119312526168569/sabs-20260422.htm) filed 2026-04-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001833214), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details SAB Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SABS, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: SAB Biotherapeutics, Inc. - **Ticker**: SABS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US78397T2024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SABS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sab-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SAB Biotherapeutics (SABS) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/sab-biotherapeutics/